The science of side effects (or, who’s afraid of 3T3-F44A2 cells?)

1 February 2003. Related: On the web.

A report from the 4th Lipodystrophy Workshop.

Mark Mascolini
IAPAC Monthly – Vol. 8, No. 11, November 2002

Including:

• From bench to bedside
• From bedside to bench
• Hard science
• Hard arteries
• More good lipid and insulin scores with atazanavir
• Lipid subclass quiz (correct answer: efavirenz)
• Lipid liabilities with d4T
• HAART, the heart, and other muscles
• Hard choices
• Switching from d4T for atrophy and high lactates
• Diet and exercise: those who can, win
• Options for facial atrophy
• Alendronate for thin bones
• Statins popular, but how potent?

Full text at:
http://ww2.aegis.org/pubs/iapac/2002/ia021102.html